Generic Name and Formulations:
Methylphenidate HCl 20mg; ext-rel tabs; dye-free; contains sucrose.
Adults and Children:
Swallow whole. <6yrs: not established. ≥6yrs: may use Metadate ER tabs in place of immediate-release products when the 8-hour dose of Metadate ER corresponds to the titrated 8-hour dose of immediate-release product; max 60mg daily.
Indications for METADATE ER:
Adults and Children:
Swallow whole. <6yrs: not recommended. ≥6yrs: may use Metadate ER tabs in place of immediate-release products when the 8-hour dose of Metadate ER corresponds to the titrated 8-hour dose of immediate-release product; max 60mg daily.
During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Severe hypertension. Angina. Cardiac arrhythmias. Heart failure. Recent MI. Hyperthyroidism. Thyrotoxicosis. Glaucoma. Surgery. History of tics or Tourette's syndrome in patient or family.
History of drug dependence or alcoholism; monitor. Structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems: not recommended. Pre-existing hypertension. Assess cardiovascular status. Psychosis. Bipolar disorder. Mania. Monitor for worsening of aggressive behavior or hostility. Seizure disorders; discontinue if occur. Risk of peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. Monitor growth, HR, BP, CBC, differential, and platelet counts. Interrupt therapy if growth suppression occurs. Reduce dose or discontinue if paradoxical worsening of symptoms occur. Re-evaluate periodically. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Avoid alcohol. Caution with pressor agents. May potentiate anticonvulsants (eg, phenobarbital, phenytoin, primidone), oral anticoagulants, tricyclics, SSRIs, phenylbutazone. May be affected by agents that alter urinary pH.
Headache, anorexia, abdominal pain, dizziness, rash, insomnia, nervousness, blood dyscrasias, weight loss, nausea, dyskinesias, tachycardia, arrhythmias; priapism, Tourette's syndrome, toxic psychosis, seizures, hypertension, visual disturbances.
Endocrinology Advisor Articles
- Gender-Affirming Hormonal Treatment and Long-Term Bone Safety
- Predictors of Disordered Eating Behaviors in Teens With Type 1 Diabetes
- Is the MiniMed 670G System Safe for Children With Type 1 Diabetes?
- Risk for Congenital Heart Defects in Offspring of Mothers With Obesity
- Behavioral Modification Improves Fertility in Polycystic Ovary Syndrome
- Familial Hypercholesterolemia: An Underdiagnosed Disease Gets a Second Look
- Insulin Analogs vs Regular Human Insulin for Type 2 Diabetes
- Depression, Anxiety Predict Physical Health Indices As Strongly As Obesity
- Vaginal Estrogen Use Not Associated With Elevated Chronic Disease Risk
- Intraoperative Monitoring of PTH May Simplify Surgical Care for Primary Hyperparathyroidism
- Linagliptin and Cardiovascular Events in Patients With Type 2 Diabetes
- Private Equity Acquisition of Physician Practices Discussed
- FDA Panel Votes on Novel Osteoporosis Treatment Evenity
- Challenges in Instituting Artificial Intelligence in Health Care
- The Role of Sex Hormones in Primary Headaches: a Review